Key Points
- Director David Habiger purchased 2,100 Boston Scientific shares at an average price of $47.59, investing nearly $100,000 and increasing his direct ownership by 13.94% to 17,160 shares.
- Boston Scientific reported quarterly adjusted EPS of $0.86, beating estimates by $0.03, while revenue rose 7.5% year over year to $5.44 billion. The company also authorized a $5 billion share buyback, covering up to 6.4% of outstanding shares.
- Analyst sentiment remains favorable, with 24 Buy, five Hold and two Sell ratings; the stock has a consensus “Moderate Buy” rating and a $71.62 average price target.
Boston Scientific Corporation (NYSE:BSX - Get Free Report) Director David Habiger bought 2,100 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Boston Scientific Stock Up 0.1%
Shares of NYSE:BSX opened at $49.35 on Friday. The business's 50 day simple moving average is $45.75 and its two-hundred day simple moving average is $60.73. The firm has a market cap of $71.53 billion, a P/E ratio of 19.98, a PEG ratio of 1.08 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.22 and a current ratio of 1.24. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50.
Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The company's quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.
Boston Scientific announced that its Board of Directors has approved a share buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. Argus reaffirmed a "hold" rating on shares of Boston Scientific in a research note on Friday, July 31st. TD Cowen decreased their price objective on Boston Scientific from $61.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Daiwa Securities Group downgraded Boston Scientific from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 29th. Canaccord Genuity Group dropped their target price on Boston Scientific from $70.00 to $66.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Finally, Stifel Nicolaus set a $60.00 target price on Boston Scientific in a research report on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $71.62.
Get Our Latest Research Report on Boston Scientific
Institutional Investors Weigh In On Boston Scientific
A number of institutional investors have recently added to or reduced their stakes in BSX. Renaissance Group LLC purchased a new position in Boston Scientific in the 4th quarter worth $28,064,000. Meiji Yasuda America Inc bought a new position in shares of Boston Scientific during the fourth quarter valued at about $4,708,000. Harvest Portfolios Group Inc. increased its holdings in shares of Boston Scientific by 6.1% in the fourth quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider's stock worth $56,956,000 after buying an additional 34,598 shares during the period. LBP AM SA lifted its stake in shares of Boston Scientific by 8.4% in the 4th quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider's stock valued at $41,419,000 after acquiring an additional 33,534 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in Boston Scientific during the 4th quarter valued at about $4,914,000. 89.07% of the stock is owned by institutional investors.
Boston Scientific Company Profile
(
Get Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
